Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Dopamine may help you tell fact from fantasy, new study suggests

NCT ID NCT05711082

Knowledge-focused Sponsor: Hôpital le Vinatier Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how dopamine, a brain chemical, influences our ability to remember whether something really happened or was just imagined. Researchers will give healthy volunteers either a dopamine-boosting drug, a dopamine-blocking drug, or a placebo, then test their memory. The goal is to better understand memory problems in conditions like schizophrenia and Parkinson's disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 39 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2024

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy volunteers who have given their written informed consent * Men and women from 18 to 45 years old * Normal or corrected vision * Being fluent in French or French for native language * Being affiliated with health insurance Exclusion Criteria: * Healthy volunteers who have given their written informed consent * Men and women from 18 to 45 years old * Normal or corrected vision * Being fluent in French or French for native language * Being affiliated with health insurance * Inadmissibility of the subject's consent or refusal * Working-memory deficit (as controlled with MMSE score\< 23) * Any past or current psychiatric or somatic condition(as controlled with the Mini International Neuropsychiatric Interview, MINI) * Any past or current neurological condition * History of cranio-cerebral trauma, arterial hypotension or hypertension, cardiological or serious medical condition * Abnormal potassium dosage (below 3.1 mmol/L or above 4.9 mmol/L) * Anormal ECG * History of schizophrenia or bipolar disorder in first-degree relatives * Alcohol-drinking and caffeine intake at least during 24 hours before each session * Drug therapy excepting contraceptives * Cardiologic or severe medical conditio * Pregnancy(checked with a pregnancy autotest), lactation, or insufficient contraceptive measure (precautionary measure) * Consumption of recreational drugs during the last 6 months * Known sensitivity to any of the study medication and their excipients * Lactose intolerance * Porphyria * Hepatic insufficiency

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neurosciences are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neurosciences

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Hospitalier le Vinatier

    RECRUITING

    Bron, 69678, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.